Pratiwi May Pamungkas, Rifkarosita Putri Ginaris , Alfina Nurrahman

Evaluation of the Use of Oral Antidiabetic Drugs in Type 2 Diabetes Mellitus Patients at the Outpatient Installation of Azizah Metro Hospital

Introduction

Evaluation of the use of oral antidiabetic drugs in type 2 diabetes mellitus patients at the outpatient installation of azizah metro hospital. Evaluate oral antidiabetic drug use in Type 2 Diabetes Mellitus outpatients at Azizah Metro Hospital. Study found 100% rational drug use for T2DM patients.

Abstract

Diabetes mellitus (DM) is a chronic metabolic disease characterized by elevated blood glucose levels (hyperglycemia). This condition arises due to impaired insulin production, the body's inability to effectively utilize insulin, or a combination of both. The rational use of antidiabetic drugs is crucial in managing blood glucose levels in diabetic patients. This study aimed to evaluate the use of oral antidiabetic drugs in patients with type 2 DM at the outpatient clinic of Azizah Metro Hospital. The research employed a descriptive design with retrospective data collection, using patient medical records from October to December 2024 as the data source. The sampling technique was total sampling, with a total of 80 patients as respondents. The majority of patients were female (77.5%), and the most prevalent age group was 56–65 years (48.75%). Most patients were on monotherapy (68.75%), with glimepiride being the most frequently prescribed drug (33.75%). The evaluation results showed that all patients (100%) met the criteria for appropriate drug use based on patient condition, indication, drug type, and dosage. In conclusion, the use of oral antidiabetic drugs in type 2 DM outpatients at Azizah Metro Hospital during the period of October–December 2024 has met the principles of rational therapy with an accuracy rate of 100%.

Review

This paper, "Evaluation of the Use of Oral Antidiabetic Drugs in Type 2 Diabetes Mellitus Patients at the Outpatient Installation of Azizah Metro Hospital," addresses a crucial aspect of patient care: the rational use of antidiabetic medications. The study's primary objective was to assess the appropriateness of oral antidiabetic drug prescriptions for Type 2 DM patients attending the outpatient clinic of Azizah Metro Hospital. Employing a descriptive, retrospective design, the researchers analyzed medical records of 80 patients from October to December 2024. Key demographic findings revealed a majority of female patients (77.5%) and a prevalence of the 56-65 age group (48.75%). Furthermore, the study identified that most patients were managed with monotherapy (68.75%), with glimepiride being the most frequently prescribed drug (33.75%). The most striking finding of this study is the reported 100% accuracy rate in the rational use of oral antidiabetic drugs, based on criteria covering patient condition, indication, drug type, and dosage. This outcome suggests a commendably high standard of pharmaceutical care and adherence to clinical guidelines within Azizah Metro Hospital's outpatient setting. Such a high level of compliance with rational drug use principles is a significant positive indicator regarding patient safety and potential treatment efficacy in this specific healthcare environment. The study also contributes by providing a clear snapshot of prescribing patterns and patient demographics for Type 2 DM management in a local hospital, which can be valuable for internal audits and quality assurance efforts. While the reported 100% accuracy rate is highly positive, a critical review warrants consideration of factors that might influence such a definitive result. The abstract does not detail the specific criteria or guidelines used for evaluating "appropriate drug use," which is crucial for reproducibility and broader applicability of the findings. Furthermore, the retrospective design over a relatively short three-month period (October–December 2024) and sole reliance on medical records might limit the depth of evaluation, as it does not account for aspects such as patient adherence, the occurrence of side effects, or actual therapeutic outcomes (e.g., HbA1c control). Future research could benefit from a more explicit description of the evaluation rubric, an extended observation period, and the inclusion of patient-reported outcomes or objective clinical indicators to provide a more comprehensive assessment.

Full Text

Comments

You need to be logged in to post a comment.